SELLAS Life Sciences Group, Inc. (SLS) Stock Analysis
Sellas is a late-stage, cash-fortified but heavily diluted AML biotech where REGAL’s Phase 3 outcome determines whether GPS becomes a CR2 maintenance standard—or the company pivots to SLS009 as its value floor.
Overview
Sellas Life Sciences enters 2026 at a major inflection point: it remains a late-stage, pre-revenue oncology biotech, but has meaningfully reduced near-term financing risk and now approaches potentially value-defining clinical catalysts. The company is effectively a two-asset story. The near-term “coin flip” is the Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML CR2 maintenance, where final analysis is triggered at 80 overall survival events; as of late Dec 2025, 72 events had occurred. Importantly, the trial’s prolonged, still-blinded duration—unusual given historically poor outcomes on best available therapy—may hint at survival separation favoring GPS, though it is not definitive. In parallel, SLS009 (a selective CDK9 inhibitor) has emerged as a high-value precision-oncology asset after Phase 2 results showed a 100% response rate in ASXL1-mutated AML, establishing a potential biomarker-enriched regulatory path. Financially, Sellas executed aggressive warrant inducements/exercises in late 2025 into Jan 2026, building an estimated ~$71.8M cash position (unaudited Dec 31, 2025) and raising >$80M gross proceeds, providing runway to reach REGAL data and expand SLS009—but at the cost of heavy dilution, expanding shares to ~170.3M by Jan 7, 2026.